List of Excipients in Branded Drug PROQUAD

PROQUAD Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

ProQuad is Merck’s live attenuated measles, mumps, rubella, and varicella vaccine for children aged 12 months through 12 years. Its excipient system is designed for viral stability during lyophilization and storage, rapid reconstitution, and acceptable pediatric tolerability. The most commercially attractive opportunities are in stabilizer systems, gelatin alternatives, lyophilization technology, cold-chain reduction, container-closure systems, and analytical control of live-virus potency.

ProQuad does not have a conventional small-molecule generic pathway. Competition is more likely to arise from separately administered MMR and varicella vaccines, new combination vaccines, procurement substitution, and manufacturing or supply advantages than from an immediate generic launch.

What excipients are used in ProQuad?

ProQuad is a preservative-free, lyophilized vaccine supplied with sterile water for reconstitution. The active viral components are measles, mumps, rubella, and varicella vaccine viruses. The formulation includes stabilizing sugars, amino-acid-derived compounds, salts, buffering agents, and hydrolyzed gelatin.[1]

Excipient or formulation component	Primary technical function	Commercial relevance
Sucrose	Protects viral particles during freezing and drying	Core lyophilization-stabilizer opportunity
Hydrolyzed gelatin	Stabilizes live viral particles and reduces surface adsorption	Potential immunogenicity, sourcing, and animal-origin concerns
Sorbitol	Cryoprotectant and bulking agent	Useful in sugar-polyol optimization
Monosodium L-glutamate	Stabilizer and tonicity-supporting excipient	Potential replacement or concentration-optimization target
Sodium phosphate salts	Buffering and pH control	Supports potency and degradation control
Potassium phosphate salts	Buffering and ionic-strength control	Relevant to pH and reconstitution performance
Sodium chloride	Tonicity and formulation balance	Standard parenteral excipient
Sodium bicarbonate	Buffering component	Supports formulation pH and viral stability
Potassium chloride	Ionic-strength adjustment	Part of the salt system
Sterile water diluent	Reconstitution vehicle	Container, fill-finish, and cold-chain opportunity

The product is supplied as a single-dose vial containing lyophilized vaccine and a separate vial or syringe of sterile diluent. The label identifies hydrolyzed gelatin and residual manufacturing-related materials, including trace antibiotics and cell-culture-derived components, as relevant product attributes.[1]

Why does the ProQuad excipient system matter?

Live attenuated viruses are more sensitive to heat, moisture, oxidation, interfacial stress, and pH variation than many conventional pharmaceutical molecules. The excipient system must protect four viral components simultaneously. This creates a more difficult optimization problem than formulating a single-antigen vaccine.

The principal formulation constraints are:

1. Maintaining minimum potency for each viral component through shelf life.
2. Avoiding interactions that disproportionately reduce varicella or mumps potency.
3. Preserving cake structure and reconstitution time after lyophilization.
4. Controlling residual moisture without damaging viral infectivity.
5. Supporting pediatric administration without preservatives or unnecessary excipient burden.

How does ProQuad’s formulation compare with other childhood vaccines?

ProQuad consolidates MMR and varicella vaccination into one injection. Its principal commercial comparator is not a generic product. It is the two-injection regimen consisting of M-M-R II plus Varivax, both manufactured by Merck.[2]

Product or regimen	Antigens	Administration burden	Excipient strategy	Competitive position
ProQuad	Measles, mumps, rubella, varicella	One injection	Combined live-virus lyophilized formulation	Convenience and schedule simplification
M-M-R II plus Varivax	MMR plus varicella	Two injections	Separate optimized formulations	Flexibility and established component use
Priorix plus varicella vaccine	MMR plus separate varicella product	Two injections	Separate formulations	Potential non-Merck MMR substitution
Future MMRV product	MMR plus varicella	One injection	New combined formulation	Requires clinical, manufacturing, and regulatory investment

A combined MMRV formulation can reduce injection burden, but it also creates potency-balancing risks. Separate products allow each viral component to use its own optimal stabilizer concentration, pH, drying cycle, and fill volume. A new MMRV product would need to demonstrate that combination benefits justify the additional formulation complexity.

What formulation technologies could improve ProQuad or a competing MMRV vaccine?

Gelatin alternatives

Hydrolyzed gelatin is one of the most commercially significant formulation targets. It provides strong stabilization for live vaccines, but it introduces:

• Animal-origin sourcing controls.
• Lot-to-lot variability.
• Religious, dietary, or cultural restrictions.
• Potential allergy-management considerations.
• Additional supplier qualification and viral or transmissible-agent controls.

Potential alternatives include recombinant gelatin, non-animal-derived hydrolysates, synthetic polymers, amino-acid combinations, and tailored sugar-polyol systems. A replacement must preserve viral potency during lyophilization and storage without increasing aggregation, adsorption, reconstitution time, or injection-site reactogenicity.

A gelatin-free ProQuad-like formulation could support premium positioning in selected markets, particularly where animal-derived excipients complicate procurement or labeling. The opportunity is technically demanding because gelatin often performs multiple functions simultaneously.

Sugar and polyol optimization

Sucrose and sorbitol are central to the freeze-drying strategy. Commercial development could focus on:

• Sucrose-to-sorbitol ratio.
• Trehalose or other disaccharide substitution.
• Reduced total solids.
• Improved cake appearance.
• Lower residual moisture.
• Faster reconstitution.
• Increased thermal stability.

A successful formulation could reduce potency loss during distribution and extend permitted temperature excursions. The value would be greatest in markets with weak cold-chain infrastructure or high transport exposure.

Amino-acid and buffer systems

Monosodium L-glutamate is used in multiple viral vaccine formulations as a stabilizing component. Alternative amino acids or combinations of amino acids could be evaluated for pH control, protein-virus surface interactions, and protection from freeze-concentration stress.

The buffer system is another opportunity. Small changes in phosphate, bicarbonate, and potassium concentrations can affect:

• Viral infectivity.
• Reconstitution pH.
• Container-closure compatibility.
• Freeze-drying behavior.
• Stability after reconstitution.

A competitor that develops a lower-complexity buffer system could gain manufacturing advantages, but the formulation would require extensive comparative stability and clinical bridging work.

Lyophilization and residual-moisture control

The commercial value of an improved excipient system is closely linked to the drying cycle. Opportunities include:

• Faster primary drying.
• Lower collapse risk.
• Better control of residual moisture.
• Reduced vial-to-vial potency variation.
• Improved resistance to thermal excursions.
• Lower energy consumption.
• Higher batch throughput.

Excipient suppliers with cycle-development expertise can capture value through formulation-development partnerships, contract development and manufacturing organization work, and proprietary stabilizer platforms.

What commercial opportunities exist in the ProQuad excipient supply chain?

The largest opportunities are adjacent to the finished product rather than direct substitution for ProQuad.

High-value opportunity areas

Opportunity	Buyer need	Likely value proposition
Recombinant or non-animal gelatin	Reduce animal-origin and sourcing concerns	Gelatin-free or animal-origin-free positioning
Advanced lyoprotectants	Improve live-virus stability	Higher retained potency and fewer stability failures
Cold-chain-tolerant formulations	Reduce distribution loss	Longer temperature-excursion tolerance
Single-dose container systems	Reduce handling and contamination risk	Faster administration and improved workflow
Low-adsorption vial coatings	Limit viral loss at surfaces	Higher recovery and lower potency variability
Sterile diluent packaging	Simplify reconstitution	Integrated syringe, dual-chamber, or user-friendly formats
Stability-indicating assays	Demonstrate viral potency	Faster release and comparability studies
Contract lyophilization	Expand manufacturing capacity	Specialized vaccine fill-finish capacity
Excipient regulatory packages	Accelerate submissions	Supplier documentation and global acceptance support

The most defensible platform opportunity is a stabilizer package that improves potency across multiple live-virus vaccines. A product limited to one MMRV formulation would have a smaller addressable market and greater customer-concentration risk.

Can excipient suppliers obtain patent protection?

Yes. Patentable subject matter may include:

• Specific excipient ratios.
• Gelatin-free stabilizer combinations.
• Defined pH and ionic-strength ranges.
• Lyophilization cycles.
• Container-closure configurations.
• Reconstitution systems.
• Formulations that retain potency after defined temperature excursions.
• Combination formulations that improve stability of a specific viral component.

Broad claims covering sucrose, sorbitol, salts, or gelatin alone would face substantial prior-art pressure. Stronger claims would connect composition to measurable performance, such as retained infectivity after a defined storage period or reduced potency loss under a defined thermal stress.

Freedom-to-operate analysis must cover formulation patents, process patents, packaging patents, and rights owned by vaccine manufacturers or excipient suppliers. A formulation that avoids the active ingredient claims of a legacy vaccine may still implicate manufacturing or delivery claims.

What patents protect ProQuad and when does ProQuad lose exclusivity?

ProQuad is a biological vaccine, not a conventional small-molecule drug. Its regulatory and competitive framework differs from the Hatch-Waxman model.

The relevant protection layers are:

Protection layer	Relevance to ProQuad
FDA biologics approval	Controls lawful marketing of the licensed product
Biologic data exclusivity	Limited period against certain follow-on approvals
Formulation patents	May cover stabilizer combinations or dosage forms
Manufacturing patents	May cover virus propagation, blending, drying, or filling
Method-of-use patents	May cover age groups, schedules, or administration methods
Trade secrets	May protect process parameters and quality controls
Regulatory know-how	Supports comparability, potency, and release strategy

The original biologic data-exclusivity period has expired for a product licensed in the mid-2000s. That does not establish that every patent has expired, but it removes the principal regulatory exclusivity barrier to development of a competing product. The FDA label and public product information do not provide a complete patent register for all historical formulation and manufacturing rights.[1,3]

Does ProQuad have Orange Book-listed patents?

The Orange Book is primarily used for FDA-approved drug products subject to the small-molecule abbreviated new drug application system. ProQuad is licensed as a biologic under a biologics license application. Its competitive analysis therefore should not rely on the Orange Book in the same way as an orally administered small-molecule product.[3]

No conventional Orange Book patent-expiration analysis should be treated as a complete assessment of ProQuad’s intellectual-property position. Relevant rights may instead appear in issued patents, continuation filings, manufacturing agreements, license arrangements, and trade-secret controls.

Are Paragraph IV challenges relevant to ProQuad?

A conventional Paragraph IV filing is generally not the principal pathway for challenging a live attenuated vaccine licensed under a biologics framework. Paragraph IV litigation is associated with abbreviated new drug applications and Orange Book-listed patents.

A competitor seeking to commercialize an MMRV vaccine would more likely pursue an independent biologics approval strategy, supported by its own clinical, manufacturing, potency, and stability package. Patent disputes could still arise, but they would not necessarily take the standard ANDA Paragraph IV form.

What generic entry risks exist for ProQuad?

Generic entry risk is low in the conventional sense. Product substitution risk is more significant.

Main competitive risks

1. A competing MMRV vaccine could reduce the value of ProQuad’s one-injection convenience.
2. Separate MMR and varicella products can substitute for ProQuad in public-sector procurement.
3. A supplier with superior cold-chain performance could win tenders in emerging markets.
4. A gelatin-free or animal-origin-free product could obtain preference in selected health systems.
5. Production interruptions or shortages could shift demand to component vaccines.
6. A lower-cost combination vaccine could pressure pricing even without formal generic substitution.

A follow-on product would face substantial barriers. Live-virus potency, lot consistency, clinical comparability, cell-substrate controls, adventitious-agent testing, and long-term stability create a high development burden. These barriers protect the incumbent even after formal data exclusivity expires.

What is the FDA regulatory status of ProQuad?

ProQuad is FDA-approved for active immunization against measles, mumps, rubella, and varicella in children from 12 months through 12 years of age.[1] It is administered subcutaneously or intramuscularly according to the prescribing information.

Important regulatory boundaries include:

• It is not indicated for infants younger than 12 months.
• It is not indicated for individuals aged 13 years or older.
• It is a live vaccine and carries contraindications related to severe immunodeficiency, pregnancy, and certain hypersensitivity conditions.
• The product requires frozen storage before reconstitution under the labeled conditions.
• It must be used promptly after reconstitution according to label instructions.

The FDA approval supports the product’s commercial role in routine pediatric vaccination but does not create a broad adult or immunocompromised-patient market.

What patent litigation and settlement risks affect ProQuad?

Publicly visible litigation risk appears lower than for high-revenue small-molecule products with extensive Orange Book litigation. The principal legal risks are more likely to involve:

• Formulation and lyophilization patents.
• Cell-culture and viral propagation methods.
• Supply and manufacturing agreements.
• Trademark and trade-dress rights.
• Procurement disputes.
• Product-liability claims involving gelatin, neomycin, or vaccine adverse events.

There is no standard assumption that a future MMRV competitor would enter after a Paragraph IV settlement. A negotiated license, manufacturing collaboration, or nonassertion agreement could be commercially more practical than patent litigation.

How strong is the ProQuad patent estate?

The commercial strength of ProQuad is likely greater than its visible patent strength. The product benefits from manufacturing complexity, clinical history, regulatory know-how, cold-chain requirements, and scale. Those barriers can delay competition even when formal exclusivity has ended.

Defensive asset	Relative strength	Reason
Regulatory history	High	Long-established safety, potency, and release experience
Manufacturing know-how	High	Live-virus production and lyophilization are difficult to replicate
Distribution scale	High	Established pediatric vaccine channels
Brand and physician familiarity	Moderate to high	Supports routine use and procurement acceptance
Formulation patents	Unclear to moderate	Historical patents may have expired or have limited scope
Orange Book protection	Low or not central	Product is a biologic vaccine
Supply-chain control	High	Specialized facilities and cold-chain logistics
Switching barriers	Moderate	Providers can use separate component vaccines

The strongest competitive barrier is operational execution. An entrant must produce all four viral components at acceptable potency and consistency, not merely reproduce a listed excipient composition.

How do licensing deals affect ProQuad commercial opportunities?

Licensing can accelerate entry into regions where local manufacturing, public procurement, or technology-transfer requirements are decisive. Potential deal structures include:

• Regional commercialization licenses.
• Fill-finish agreements.
• Technology-transfer arrangements.
• Non-animal excipient licenses.
• Joint development of thermostable formulations.
• Contract manufacturing agreements.
• Public-sector supply commitments.

An excipient company could license a stabilizer platform to an established vaccine manufacturer instead of pursuing an independent MMRV product. This model reduces clinical and regulatory risk and creates a broader customer base across measles, mumps, rubella, varicella, and other live viral vaccines.

What revenue exposure does ProQuad create for Merck and suppliers?

Merck does not generally disclose ProQuad revenue as a separate public line item. It reports vaccines within broader product categories, limiting reliable standalone revenue analysis.[4]

Revenue exposure is concentrated in:

• U.S. pediatric immunization.
• Government and managed-care purchasing.
• International public-health programs.
• Seasonal procurement cycles.
• Availability of M-M-R II and Varivax as substitutes.
• Manufacturing capacity for live viral vaccines.

For excipient suppliers, the addressable market is broader than ProQuad sales. A validated formulation component can be used in multiple live-virus products, creating repeat demand and reducing dependence on a single branded vaccine.

What is the best excipient strategy for a ProQuad competitor?

The strongest strategy would combine four objectives:

1. Maintain or improve potency across all four viral components.
2. Remove hydrolyzed gelatin without increasing manufacturing complexity.
3. Improve thermal tolerance and reduce cold-chain losses.
4. Use a scalable, globally accepted excipient supply chain.

A competitor should avoid positioning based only on a different excipient list. Regulatory and commercial value will depend on demonstrated performance: retained infectivity, shelf life, reconstitution speed, stability after temperature excursions, and consistent batch release.

Key Takeaways

• ProQuad uses a lyophilized live-virus formulation built around sucrose, sorbitol, hydrolyzed gelatin, monosodium L-glutamate, phosphate buffers, bicarbonate, and salts.
• Gelatin replacement is the clearest formulation opportunity, but it must preserve multi-virus potency through freeze-drying and storage.
• Cold-chain tolerance, lyophilization efficiency, and improved container systems offer commercial opportunities beyond the excipient itself.
• ProQuad’s principal competition is the separate MMR plus varicella regimen, not a conventional generic.
• Paragraph IV litigation is not the primary competitive pathway for this biologic vaccine.
• The original biologic data-exclusivity period has expired, but manufacturing complexity remains a substantial barrier to entry.
• Standalone ProQuad revenue is not publicly disclosed by Merck.
• The most valuable licensing opportunity is a platform stabilizer or gelatin-free formulation applicable across multiple live viral vaccines.

FAQs

Can ProQuad be reformulated without gelatin?

Yes, but a gelatin-free replacement would require extensive formulation, stability, potency, and clinical comparability work. Recombinant gelatin and synthetic stabilizer systems are potential approaches.

Does ProQuad require a preservative?

No. ProQuad is supplied as a preservative-free, single-dose lyophilized vaccine with a sterile diluent.[1]

Can a company launch a generic version of ProQuad?

A conventional generic launch is unlikely. A competitor would generally need to pursue a biologics approval strategy for its own live-virus combination vaccine.

Is ProQuad protected by an active Orange Book patent?

The Orange Book is not the primary patent-clearance tool for this biologic vaccine. Competitors should review issued patents, continuations, manufacturing rights, and licensing arrangements separately.[3]

Which excipient improvement would have the highest commercial value?

A formulation that eliminates animal-derived gelatin while improving thermal stability would likely have the strongest commercial value, especially if the technology applies to several live viral vaccine products.

References

1. Merck & Co., Inc. (2023). ProQuad (measles, mumps, rubella and varicella virus vaccine live) prescribing information. U.S. Food and Drug Administration.

2. Centers for Disease Control and Prevention. (2024). Child and adolescent immunization schedule by age. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. Merck & Co., Inc. (2024). Annual report and Form 10-K. Merck & Co., Inc.